Observational study assessing genetic variants' impact on chemotherapy outcomes in cancer patients, suggesting potential for tailored treatment approaches.
A sizable minority of oncology patients bear variants of DPYD with reduced activity and may be at increased risk of fluoropyrimidine toxicities if treated at full doses. However, variability within the same genotype exists.
No takes yet. Share an insight, caveat, or question.
Rosso et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: